ミトコンドリアDDSが拓く新しい薬剤学  [in Japanese] Mitochondrial DDS Opens Innovative Pharmaceutics  [in Japanese]

Access this Article

Author(s)

    • 山田 勇磨 Yamada Yuma
    • 北海道大学大学院薬学研究院薬剤分子設計学研究室 Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University

Abstract

  A variety of human diseases, including neurodegenerative disorders, ischemic heart disease, diabetes, and cancer have been reported to be associated with mitochondrial dysfunction. Because of this, mitochondrial therapy is expected to be useful and productive in the treatment of such diseases. We previously reported on the development of a MITO-Porter, a liposome-based nanocarrier that permits macromolecular cargos to be delivered into mitochondria <i>via</i> membrane fusion. Intracellular observations using the green fluorescence protein as a model macromolecule provided confirmation that a macromolecule could be delivered to mitochondria in living cells by the MITO-Porter. Here, we present our current findings on the development of mitochondrial medicine and mitochondrial gene therapy based on our mitochondrial drug delivery system (DDS). In this review, we propose “mitochondrial DDS” as a theme for “DDS research for innovative drug development” and discuss the contribution of mitochondrial DDS to innovative drug development.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 136(1), 55-62, 2016

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130005115195
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    JPN
  • ISSN
    0031-6903
  • NDL Article ID
    027052238
  • NDL Call No.
    Z19-411
  • Data Source
    NDL  J-STAGE 
Page Top